Supreme Court denies leave in infliximab patent infringement action
On January 8, 2021, the Supreme Court of Canada denied leave to Janssen and Kennedy Trust (Docket No. 39099) with respect to the
Federal Court of Appeal’s decision remitting to the trial judge the reconsideration of issues of obviousness and anticipation (as previously reported).
Amgen seeks leave to appeal decision invalidating its filgrastim patent
As previously reported, the Federal Court of Appeal had dismissed Amgen’s appeal from a decision invalidating claims of a patent relating to filgrastim (Amgen’s NEUPOGEN and Pfizer’s biosimilar product NIVESTYM). On January 4, 2021, Amgen applied to the Supreme Court of Canada for leave to appeal (Docket No. 39530).
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Dexlansoprazole formulation patent invalid and not infringed by Apotex
On February 7, 2024, the Federal Court dismissed Takeda’s action under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations in relation to dexlansoprazole (Takeda’s DEXILANT).Read More -
FCA upholds inducement of infringement findings relating to paliperidone palmitate
On January 12, 2024, the Federal Court of Appeal (FCA) dismissed both appeals: Apotex Inc v Janssen Inc, 2024 FCA 9 and Pharmascience Inc v Janssen Inc, 2024 FCA 10.Read More -
Federal Court of Appeal affirms paliperidone palmitate claims are not unpatentable methods of medical treatment
On February 1, 2024, the Federal Court of Appeal (FCA) dismissed Pharmascience’s appeal. Per the FCA, whether a claimed dosing regimen is an unpatentable method of medical treatment cannot be based ex...Read More